CTKB

Cytek Biosciences, Inc.

Laboratory Analytical Instruments · SIC 3826CIK 1831915Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$201.0M

Net Income FY2025

$(67.0M)

EPS (Basic, as reported)

—

Net Margin FY2025

-33.0%

ROE FY2025

-19.5%

Total Equity

$342.0M

Shares Out

130M

Business description

Cytek Biosciences, Inc. — Laboratory Analytical Instruments. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 93 → 201 +16.7% CAGR

Fiscal yearFY2020⚑FY2021⚑FY2022FY2023FY2024FY2025

Revenue93128164193200201

Cost of revenue(41)(49)(63)(84)(89)(97)

Gross profit5279101109111104

Research & development(14)(24)(35)(44)(39)(36)

Selling & marketing(15)(25)(33)(49)(49)(49)

General & administrative(9)(21)(35)(44)(43)(59)

Total operating expenses(38)(70)(103)(137)(132)(145)

Operating income149(2)(28)(21)(40)

Interest expense0(2)(3)(2)(5)0

Interest & investment income005652

Other income (expense), net1(3)3121511

Pre-tax income1461(16)(6)(30)

Income tax expense(5)(3)(1)(4)0(37)

Net income1932(12)(6)(67)

EPS — basic$0.11$0.00$0.02($0.09)——

EPS — diluted$0.10$0.00$0.02($0.09)——

Shares outstanding — basic (M)2977135135131128

Shares outstanding — diluted (M)3382139135131128

⚑ Weighted-average shares changed ×2.66 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.75 between FY2021 and FY2022 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.